A prospective observational study for impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy
Not Applicable
Completed
- Conditions
- cancer
- Registration Number
- JPRN-UMIN000018544
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Any other inadequacy for this study 2) Presence of brain metastases 3) Hypercalcemia 4) Gastrointestinal obstruction 5) other medication or participation in studies that might modify the usual chemotherapy induced nausea and vomiting pattern or the emetogenous level of the chemotherapy regimen received
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of no impact on patient's QOL during 0 to 120 hours (all phase) after an anticancer agent dosage start
- Secondary Outcome Measures
Name Time Method 1) Rate of no impact on patient's QOL during 0 to 24 hours (acute phase) after an anticancer agent dosage start 2) Rate of no impact on patient's QOL during 24 to 120 hours (delay phase) after an anticancer agent dosage start 3) Complete protection rate during 0 to 24 hours (acute phase) after an anticancer agent dosage start 4) Complete protection rate during 24 to 120 hours (delay phase) after an anticancer agent dosage start